Pancreatic Cancer Research

ResearcherUniversity Health NetworkActive in the last 2 years

Tao Wang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-4355-149X; OpenAlex author ID A5100453525. Sources: OpenAlex.

Their work

Papers
8 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
36
Papers, trials and grants by year

2015: 1 paper · 2016: 1 paper · 2017: none · 2018: none · 2019: none · 2020: 1 paper · 2021: none · 2022: none · 2023: 2 papers · 2024: 1 paper · 2025: 2 papers

Papers 8

  1. A platform for multisite immune profiling of premetastatic pancreatic cancer at single-cell resolution. Co-author DOI 10.1007/s00262-025-04146-5↗
  2. KRAS G12D-driven pentose phosphate pathway remodeling imparts a targetable vulnerability synergizing with MRTX1133 for durable remissions in PDAC. First author DOI 10.1016/j.xcrm.2025.101966↗
  3. Pancreatic cancer-derived exosomal miR-510 promotes macrophage M2 polarization and facilitates cancer cell aggressive phenotypes. Co-author DOI 10.1007/s13577-024-01144-0↗
  4. miR-4299 inhibits tumor progression in pancreatic cancer through targeting ADAM17. Co-author DOI 10.1007/s11010-022-04617-8↗
  5. Targeting UBE2T Potentiates Gemcitabine Efficacy in Pancreatic Cancer by Regulating Pyrimidine Metabolism and Replication Stress. Co-author DOI 10.1053/j.gastro.2023.02.025↗
  6. Rho guanine nucleotide exchange factor ARHGEF10 is a putative tumor suppressor in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41388-019-0985-1↗
  7. A renewed model of pancreatic cancer evolution based on genomic rearrangement patterns. Co-author DOI 10.1038/nature19823↗
  8. miR-663 attenuates tumor growth and invasiveness by targeting eEF1A2 in pancreatic cancer. Co-author DOI 10.1186/s12943-015-0315-3↗

Closest collaborators

The 25 strongest of 36 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yaqun Yu · 2 shared papers, 2023–2024 · strength 0.39
  2. Lin Ye · 2 shared papers, 2023–2024 · strength 0.39
  3. Xiangyan Jiang · 2 shared papers, 2023–2025 · strength 0.33
  4. Zeyuan Yu · 2 shared papers, 2023–2025 · strength 0.33
  5. Junhong Guan · 2 shared papers, 2023–2025 · strength 0.33
  6. Zuoyi Jiao · 2 shared papers, 2023–2025 · strength 0.33
  7. Julia Button · 1 shared paper, 2025 · strength 0.20
  8. Erika J. Crosby · 1 shared paper, 2025 · strength 0.20
  9. Austin M. Eckhoff · 1 shared paper, 2025 · strength 0.20
  10. Dan German Blazer · 1 shared paper, 2025 · strength 0.20
  11. Michael E. Lidsky · 1 shared paper, 2025 · strength 0.20
  12. Sabino Zani · 1 shared paper, 2025 · strength 0.20
  13. Elishama N. Kanu · 1 shared paper, 2025 · strength 0.20
  14. Ethan S. Agritelley · 1 shared paper, 2025 · strength 0.20
  15. Peter J. Allen · 1 shared paper, 2025 · strength 0.20
  16. Daniel P. Nussbaum · 1 shared paper, 2025 · strength 0.20
  17. Yuman Dong · 1 shared paper, 2025 · strength 0.18
  18. Junhong Liu · 1 shared paper, 2023 · strength 0.17
  19. Ming‐Sound Tsao · 2 shared papers, 2016–2020 · strength 0.17
  20. Joella Joseph · 1 shared paper, 2020 · strength 0.13
  21. Nikolina Radulovich · 1 shared paper, 2020 · strength 0.13
  22. Guoqiang Zhao · 1 shared paper, 2015 · strength 0.06
  23. Wenqiao Zang · 1 shared paper, 2015 · strength 0.06
  24. Min Li · 1 shared paper, 2015 · strength 0.06
  25. Thomas J. Hudson · 1 shared paper, 2016 · strength 0.04

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.